AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A compound represented by formula (I)

T
$$(CH_2)_n$$
 $-Y$ $-G$ $-D$ (I) OH

wherein is a single bond or a double bond,

is α -configuration, β -configuration or a voluntary mixture of α -configuration and β -configuration,

D is -COOR1-or-tetrazory1,

R¹ is hydrogen or C1-4 alkyl,

G is ringA-or C1-4 alkylene,

ringA is

R² is a halogen atom, C1-4 alkyl or C1-4 alkoxy,

p is 0 or an integer of 1-4,

when p is 2 or more, plural R²'s are the same or different,

Y is a single bond or -S-,

T is oxygen or sulfur,

X is -CH₂-, -O- or -S-,

ringB is C3-7 cycloalkyl-optionally substituted,

$$(R^3)_q \qquad (R^3)_q \qquad (R^3$$

wherein R³ is (1) a halogen atom, (2) C1-4 alkyl optionally substituted with 1-5 of halogen atom(s), (3) C1-4 alkoxy optionally substituted with 1-5 of halogen atom(s), (4) C1-4 alkyl substituted with C1-4 alkoxy, (5) phenyl or (6) 3- to 15- membered mono-, bi- or triheterocyclic aryl containing 1 to 4 hetero atom(s) selected from the group consisting of oxygen, nitrogen and sulfur atom(s) which may be partially or fully saturated, and (5) phenyl or (6) heterocyclic aryl in R³ is optionally substituted with 1-3 of (a) halogen atom(s), (b) C1-4 alkyl, (c) C1-4 alkoxy and/or (d) nitro,

q is 0 or an integer of 1-5, when q is 2 or more, plural R^3 's are the same or different, and n is an integer of 1-4,

a salt thereof, a solvate thereof, a cyclodextrin clathrate thereof, or a prodrug thereof.

2. (canceled).

3. (currently amended): The compound according to claim 1, which is represented by formula (I-1):

$$(CH_2)_n - S - G^1 - COOR^1$$

X

14

OH

OH


(I-1)

wherein G¹ is ringA¹ or C1-4 alkylene,

ringA¹ is

wherein left-pointing arrow represents binding to S, and right-pointing arrow represents binding to COOR¹,

ringB1 is C3-7 cycloalkyl,



ringB¹ may be substituted with a halogen atom, C1-4 alkyl, phenyl, methoxymethyl, trifluoromethyl and/or trifluoromethoxy,

other symbols have the same meanings as described in claim 1, and wherein when T is oxygen, X is -CH₂-, and when n is an integer of 2-4, G^1 is ringA¹.

(currently amended): The compound according to claim 3, which is 4. selected from the group consisting of: (1) (15α,13E) 9 oxo 15 hydroxy-16 (3 phenylphenyl)-17,18,19,20 tetranol-5 thia 8aza-10 oxaprost-13 enoic acid, (2) (15α,13E)-9-oxo-15-hydroxy-16-(3-ethylphenyl) 17,18,19,20 tetranol-5-thia-8-aza-10-oxaprost-13-enoic-acid, (3) (15α,13E)-9 oxo-15 hydroxy-16 (3-chloro-4-fluorophenyl)-17,18,19,20-tetranol-5thia 8 aza 10 oxaprost 13 enoic acid, (4) (15\alpha,13\text{E}) 9-oxo-15-hydroxy-16-(naphthalene-2-yl)-17,18,19,20-tetranol-5-thia-8aza-10-exaprost-13-enoic acid, (5) (15α,13E)-9-oxo-15-hydroxy-16-(3-trifluoromethoxyphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid, (6) (15α,13E) 9-oxo-15-hydroxy-16-(4-fluoro-3-phenylphenyl)-17,18,19,20-tetranol-5thia-8-aza-10-oxaprost-13-enoic acid, (7) (15α,13E) 9 oxo-15 hydroxy 16 (4-fluoro-3-methylphenyl) 17,18,19,20-tetranol-5thia-8-aza 10-oxaprost-13-enoic acid,

5

(8) (15α,13E)-9-oxo-15-hydroxy-16-(3,5-difluorophenyl)-17,18,19,20-tetranol-5-thia-8-

(9) (15α,13E) 9-oxo-15-hydroxy 16-(3-fluorophenyl) 17,18,19,20-tetranol-5-thia-8-

aza 10-oxaprost-13-enoie acid,

aza-10-oxaprost-13-enoie acid,

- (10) (15α,13E) 9-oxo-15-hydroxy-16-(4-fluoro-3-trifluoromethylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic-acid,
- (11) (15α,13E) 9 oxo 15 hydroxy-16 (3-trifluoromethylphenyl) 17,18,19,20-tetranol-5-thia-8-aza-10 oxaprost-13 enoic acid,
- (12) $(15\alpha,13E)$ -9 exe-15-hydroxy-16-(3,4-difluorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-exaprost-13-eneic acid,
- (13) (15α,13E) 9 oxo-15-hydroxy-16-phenyl-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (14) (15α,13E) 9 oxo-15-hydroxy 16 (3-propylphenyl) 17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (15) (15\alpha,13\text{E})-9-oxo-15-hydroxy-16-(3-methoxymethylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (16) (150,13E) 9 oxo 15 hydroxy-16 (3-ethyl-4-fluorophenyl) 17,18,19,20 tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (17) (15α,13E)-9-oxo-15-hydroxy-16-phenyl-5 (4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-oxaprost-13-ene,
- (18) (15α,13E)-9 oxo-15-hydroxy-16 (3-methylphenyl)-5 (4-carboxythiazol 2 yl)-1,2,3,4,17,18,19,20 octanol-5 thia 8 aza-10 oxaprost 13 ene,
- (19) (15\alpha,13E)-9-oxo-15-hydroxy 16-(4-fluorophenyl)-5-(4-carboxythiazol-2-yl)-1.2.3.4.17.18.19.20-octanol-5-thia-8-aza-10-oxaprost-13-ene,

- (20) (15α,13E)-9-oxo-15-hydroxy-16 (naphthalene-2 yl)-5 (4-carboxythiazol-2 yl)-1,2,3,4,17,18,19,20 octanol-5-thia-8-aza-10-oxaprost-13-ene,
- (21) (15α,13E) 9 oxo 15 hydroxy 16 (3-phenylphenyl) 5 (4-carboxythiazol-2-yl) 1,2,3,4,17,18,19,20 octanol-5-thia 8 aza-10-oxaprost-13-ene,
- (22) (15α,13Ε) 9 οχο 15 hydroxy-16 (3-phenylphenyl) 5 (5 carboxythiophene-2-yl) 1,2,3,4,17,18,19,20 octanol-5-thia 8 azaprost-13 ene,
- (23) (15\alpha,13\text{E})-9-oxo-15-hydroxy-16 (naphthalene-2-yl)-5 (5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20 octanol-5-thia-8-azaprost-13-ene,
- (24) (15α,13E)-9-oxo-15-hydroxy-16-(4-fluoro-3 phenylphenyl)-5 (5-carboxythiophene-2-vl)-1.2.3.4.17.18.19.20-octanol-5-thia-8-azaprost-13-ene,
- (25) (15α,13E) 9-oxo-15-hydroxy-16-(3-ethylphenyl) 5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (26) (15α,13E) 9-oxo 15-hydroxy 16 (3-methylphenyl) 5 (5-carboxythiophene 2-yl) 1,2.3,4,17,18,19,20 octanol-5 thia 8-azaprost 13-ene,
- (27) (15α,13E) 9 oxo-15 hydroxy-16-(3-trifluoromethoxyphenyl)-5-(5-carboxythiophene-2-yl) 1,2,3,4,17,18,19,20-octanol-5 thia-8-azaprost-13-ene,
- (28) (15α,13E)-9-oxo-15-hydroxy-16-(4-fluoro-3-phenylphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (29) (15α,13E)-9-oxo-15-hydroxy-16-(3-ethylphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,

- (30) (15α,13E) 9 oxo-15-hydroxy-16-(naphthalene-2 yl) 5 (4-carboxythiazol-2-yl) 1,2,3,4,17,18,19,20 octanol-5 thia-8-azaprost-13-ene,
- (31) $(15\alpha,13E)$ -9-oxo-15-hydroxy-16-(3-trifluoromethoxyphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (32) $(15\alpha,13E)$ -9-oxo-15-hydroxy-16-(3-chloro-4-fluorophenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (33) (15α,13E) 9 oxo-15-hydroxy-16-cyclopropyl-5 (4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20 octanol 5-thia-8-azaprost-13-ene,
- (34) (15α,13E)-9-oxo-15-hydroxy-16-eyelohexyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (35) (15α,13E)-9-oxo-15-hydroxy-16-(4-fluorophenyl)-5-(5-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene, and
- (36) (15α,13E) 9 oxo-15-hydroxy-16-cyclobutyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (37) (15α,13E)-9-oxo-15-hydroxy-16-(4-chlorophenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (38) (15α,13E)-9-oxo-15-hydroxy-16-cycloheptyl-5 (4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (39) (15α,13E) 9 oxo-15 hydroxy 16 (indane-2-yl) 5 (4-carboxythiazol-2-yl) 1.2.3.4.17.18.19.20 octanol-5 thia 8-azaprost 13-ene,

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111 U.S. Application No.: 10/542,724

- (40) (15α,13E)-9-oxo-15 hydroxy-16-(tetrahydropyran 4-yl)-5 (4 carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5 thia-8-azaprost-13-ene,
- (41) (15α,13E) 9 oxo 15 hydroxy 16 (7-methylnaphthalene 2-yl) 5 (4-carboxythiazol 2-yl) 1,2,3,4,17,18,19,20 octanol-5 thia 8-azaprost 13 ene,
- (42) (15α,13E) 9-oxo-15-hydroxy-16-(4-fluorophenyl) 17,18,19,20-tetranol-5,10-dithia-8-azaprost-13-enoic acid,
- (43) (15α,13Ε)-9-oxo-15-hydroxy-16 (4-fluorophenyl)-17,18,19,20-tetranol-6-thia-8-azaprost-13-enoic acid,
- (44) (15\alpha,13E)-9-oxo-15-hydroxy-16-(3-methylphenyl)-17,18,19,20-tetranol-6-thia-8-azaprost-13-enoic acid, and
- (45) (15α,13E)-9-thioxo-15 hydroxy-16 (4-fluorophenyl)-17,18,19,20 tetranol-5 thia-8-azaprost-13 enoic acid.
- 5. (currently amended): The compound according to claim 1, which is represented by formula (I-2):

$$(CH_2)_2$$
 $-G^2$ $-D$ $(I-2)$

wherein G2 is

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111 U.S. Application No.: 10/542,724

wherein left-pointing arrow represents binding to $-(CH_2)_2$ -, and right-pointing arrow represents binding to D,

R⁴ is (1) a halogen atom, (2) C1-4 alkyl, (3) C1-4 alkoxy, (4) C1-4 alkyl optionally substituted with 1-5 of halogen atom(s), (5) C1-4 alkoxy optionally substituted with 1-5 of halogen atom(s), (6) phenyl or (7) 3- to 15- membered mono-, bi- or tri-heterocyclic aryl containing 1 to 4 hetero atom(s) selected from the group consisting of oxygen, nitrogen and sulfur atom(s) which may be partially or fully saturated, and (6) phenyl or (7) heterocyclic in the R⁴ may be substituted with 1-3 of (a) a halogen atom(s), (b) C1-4 alkyl, (c) C1-4 alkoxy and/or (d) nitro,

r is an integer 1 to 5, and other symbols have the same meanings as described in claim 1.

- 6. (currently amended): The compound according to claim 5, which is selected from the group consisting of:
- (1) (15α,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3,5-dimethylphenyl)-2,3,4,5,17,18,19,20-octanol-8 azaprost-13-enoic acid,
- (2) (15α,13E)-1,6-(1,4-interphenylene)-9-oxo-15 hydroxy-16 (3 (benzothiazol-2-yl)phenyl) 2,3,4,5,17,18,19,20 octanol-8-azaprost-13-enoic acid,

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111 U.S. Application No.: 10/542,724

- (3) (15α,13E)-1,6 (1,4-interphenylene)-9 oxo-15-hydroxy-16 (4-fluorophenyl)-2,3,4,5,17,18,19,20 octanol-8-azaprost-13-enoic acid,
- (4) $(15\alpha,13E)$ -9-oxo-15-hydroxy-16-(3-(5-methylbenzothiazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (5) (15α,13E) 1,6 (1,4-interphenylene) 9-oxo-15-hydroxy-16-(3 (5-methylbenzoxazol-2-yl)phenyl) 2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (6) $(15\alpha,13E)$ -9-oxo-15-hydroxy-16-(3-(6-methylbenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (7) (15α,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(6-methylbenzoxazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (8) (15α,13E)-1,6 (1,4-interphenylene) 9-oxo-15-hydroxy-16 (3-(4-methylbenzothiazol-2-yl)phenyl) 2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- $(9) \qquad (15\alpha,13E) 9 oxo 15 hydroxy 16 (3 (4 methylbenzothiazol 2 yl)phenyl) 5 (4 carboxythiazol 2 yl) 1,2,3,4,17,18,19,20 octanol 5 thia 8 azaprost 13 ene,$
- (10) (15α,13E)-1,6-(2-fluoro-1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (11) (15α,13E)-1,6-(3-methyl-1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl) 2,3,4,5,17,18,19,20 octanol-8 azaprost-13-enoic acid,
- $(12) \qquad (15\alpha,13E)-9-oxo-15-hydroxy-16-(3-(5,7-dimethylbenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,$

- (13) $(15\alpha, 13E)$ -9-oxo-15-hydroxy-16-(3-(5-chlorobenzothiazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (14) (15α,13E) 1,6 (1,4-interphenylene) 9-oxo-15-hydroxy 16-(3-(5-chlorobenzothiazol-2-yl)phenyl) 2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (15) (15α) -9-oxo-15-hydroxy-16-(3-(2,4-dimethylphenyl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (16) $(15\alpha,13E)$ -9-oxo-15-hydroxy-16-(3-(3,4-dimethylphenyl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene, and
- (17) (15α,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3,4-difluorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (18) (15α,13E)-1,6-(2-methyl-1,4-interphenylene)-9-oxo-15 hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- $(19) \qquad (15\alpha,13E)-9-oxo-15-hydroxy-16-(3-(5-chlorobenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,$
- (20) (15α,13E) 1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16 (3-methyl-4-fluorophenyl)-2,3,4,5,17,18,19,20 octanol-8-azaprost-13-enoic acid,
- (21) (15α,13E) -1,6-(1,4-interphenylene) 9-oxo-15-hydroxy-16-(3-chloro-4-fluorophenyl) -2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (22) (15\alpha,13\text{E})-1,6-(3-methoxy-1,4-interphenylene) 9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

Attorney Docket Q89067

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111 U.S. Application No.: 10/542,724

- (23) (15α,13E)-9-oxo-15-hydroxy 16-(3-trifluoromethoxyphenyl)-17,18,19,20-tetranol-5-thia-8-azaprost 13-enoic acid,
- (24) (15α,13Ε)-9-oxo-15-hydroxy-16-(3,5-difluorophenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid,
- (25) (15α,13E) 9-oxo-15-hydroxy-16-(3-(phenyl)phenyl)-17,18,19,20 tetranol-5-thia-8-azaprost-13-enoic acid,
- (26) (15\alpha,13E)-9-oxo-15-hydroxy-16 (3-(4-fluorophenyl)phenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid, and
- (27) (15α,13E) 9 oxo 15 hydroxy 16-(3 phenyl 4 fluorophenyl) 17,18,19,20 tetranol-5-thia-8 azaprost-13-enoic acid.
- 7. (previously presented): A pharmaceutical composition comprising the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof, a cyclodextrin clathlate thereof, or a prodrug thereof, and a pharmaceutically acceptable carrier.
 - 8-10. (canceled).
- 11. (previously presented): The compound according to claim 1, wherein n is 1 or 2.